Combined interferon alpha with levamisole in patients with metastatic renal cell carcinoma
International Urology and Nephrology, cilt.33, sa.3, ss.457-459, 2001 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 33 Sayı: 3
- Basım Tarihi: 2001
- Doi Numarası: 10.1023/a:1019510628249
- Dergi Adı: International Urology and Nephrology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.457-459
- Ankara Üniversitesi Adresli: Evet
Özet
To evaluate the efficacy and toxicity of interferon alpha-2b (IFN-α2b) and levamisole treatment regimen in patients with metastatic renal cell carcinoma (RCC). Seventeen patients with metastatic RCC were treated using recombinant IFN-α2b at a dose of 10 MU/m2 body surface subcutaneously three times in a week, for 3 months, with levamisole 50 mg t.d.s orally on days 1-3 on alternate weeks. The mean follow-up period was 10.7 (range 2-23) months. We achieved 1 complete response (lasting for 12+ months) and 1 partial response (lasting for 15 months), for an objective response rate of 11.7%. A further 7 patients (41%) had a stabilization of disease. The overall toxicity was moderate, with mainly grade I or II side effects. Grade III toxicities reported among 3 patients including vomiting (2 patients) and anorexia (1 patient). There was no treatment related death. Although additions of levamisole to IFN-α do not result in any significant increase in treatment toxicity, the response rate appears to be no better than IFN-α monotherapy reported in the literature.